In the wake of the increase in Current Liabilities in the first quarter 2023, Quick Ratio fell to 2.96 above Heska Corporation average.

Within In Vitro & In Vivo Diagnostic Substances industry 2 other companies have achieved higher Quick Ratio than Heska in first quarter 2023. While Quick Ratio total ranking in the first quarter 2023 has deteriorated compared to the prior quarter from 848 to 1201.

Explain Quick Ratio?
How much Cash & cash equivalents HSKA�s has?
What are HSKA�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

HSKA Quick Ratio	(Mar 31 2023) Q1	(Dec 31 2022) Q4	(Sep 30 2022) Q3	(Jun 30 2022) Q2	(Mar 31 2022) Q1
Y / Y Current Liabilities Change	4.36 %	-5.07 %	-3.54 %	-4.88 %	7.26 %
Y / Y Cash & cash equivalent Change	-27.52 %	-29.95 %	-27.74 %	-29.87 %	-27.56 %
Quick Ratio MRQ	2.96	3.76	4.4	4.36	4.26
HSKA's Total Ranking	# 1201	# 848	# 789	# 799	# 812
Seq. Current Liabilities Change	1.43 %	13.96 %	-7.26 %	-2.65 %	-7.73 %
Seq. Cash & cash equivalent Change	-20.05 %	-2.77 %	-6.31 %	-0.47 %	-22.74 %

Quick Ratio first quarter 2023 Company Ranking
Within:	No.
In Vitro & In Vivo Diagnostic Substances Industry	# 3
Healthcare Sector	# 574
Overall Market	# 1201

Quick Ratio Statistics
High	Average	Low
8.73	1.72	0.19
(Mar 31 2020)		(Jun 30 2017)

Financial Statements
Heska's Current Liabilities	$ 42 Millions	Visit HSKA's Balance sheet
Heska's Cash & cash equivalent	$ 125 Millions	Visit HSKA's Balance sheet
Source of HSKA's Sales		Visit HSKA's Sales by Geography

Cumulative Heska's Quick Ratio

HSKA's Quick Ratio for the trailling 12 Months

HSKA Quick Ratio	(Mar 31 2023) 12 Months	(Dec 31 2022) 12 Months	(Sep 30 2022) 12 Months	(Jun 30 2022) 12 Months	(Mar 31 2022) 12 Months
Y / Y Current Liabilities TTM Growth	-2.33 %	-1.77 %	0.24 %	3.94 %	12.74 %
Y / Y Cash & cash equivalent TTM Growth	-28.87 %	-28.78 %	-8.01 %	20.89 %	76.95 %
Quick Ratio TTM	3.84	4.18	4.54	4.89	5.27
Total Ranking TTM	# 4214	# 2828	# 3848	# 807	# 4110
Seq. Current Liabilities TTM Growth	1.12 %	-1.39 %	-0.83 %	-1.24 %	1.7 %
Seq. Cash & cash equivalent TTM Growth	-7.18 %	-9.18 %	-7.81 %	-8.47 %	-7.07 %

Quick ratio ranking by company, industry and sector >> Back to HSKA Financial Strength Comparisons >> Go to Compare HSKA Quick Ratio to its Competitors

On the trailing twelve months basis Due to rise in Current Liabilities in the Q1 2023 to $42.30 millions, cumulative Quick Ratio decreased to 3.84 above the HSKA average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within In Vitro & In Vivo Diagnostic Substances industry 16 other companies have achieved higher Quick Ratio than Heska. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2022 from 2828 to 4214.

Explain Quick Ratio?
How much Cash & cash equivalents HSKA�s has?
What are HSKA�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the In Vitro & In Vivo Diagnostic Substances Industry	# 17
Healthcare Sector	# 1132
Within the Market	# 4214

trailing twelve months Quick Ratio Statistics
High	Average	Low
5.77	1.86	0.32
(Dec 31 2021)		(Sep 30 2017)

Companies with similar Quick Ratio in the quarter ending Mar 31 2023, within In Vitro & In Vivo Diagnostic Substances Industry	Quick Ratio	Mar 31 2023 MRQ Cash & cash equivalent	Mar 31 2023 MRQ Current Liabilities
Heska Corporation	2.96	$ 125.209 Millions	$ 42.298 Millions
Biomerica Inc	2.40	$ 3.345 Millions	$ 1.395 Millions
Neogen Corporation	1.71	$ 183.214 Millions	$ 107.155 Millions
Lantheus Holdings Inc	1.70	$ 470.863 Millions	$ 276.388 Millions
Cardio Diagnostics Holdings Inc	1.47	$ 6.708 Millions	$ 4.563 Millions
Aspira Women s Health inc	1.29	$ 7.535 Millions	$ 5.828 Millions
Insight Molecular Diagnostics Inc	1.25	$ 11.803 Millions	$ 9.430 Millions
Achieve Life Sciences Inc	0.81	$ 16.514 Millions	$ 20.301 Millions
Immucell Corporation	0.81	$ 3.096 Millions	$ 3.838 Millions

Date modified: 2026-09-12T06:18:48+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.